Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

yourEra vs Gala Health

yourEra
Graded #23

Lower grade

vs+2
Gala Health
Graded #8

Higher grade

The verdict

Gala Health takes it — 86/100 to 84/100, but only just.

Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A low-entry compounded tirzepatide program (from $149 microdose) that reaches all 50 states and keeps a brand-name Ozempic path open — a rare combination this far up the value tier. yourEra is close behind and may still be the better fit — see the factor split below.

Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGala Health +8
82
90
Dose & formulationGala Health +1
82
83
Clinical oversightEven
85
85
Labs & monitoringyourEra +2
85
83
FulfillmentGala Health +2
86
88
Contract termsGala Health +1
85
86
yourEra · left barGala Health · right bar

The numbers

MetricyourEraGala Health
WeighScore84/10086/100
GradeBB
Scorecard rank#23#8
Semaglutide$199/moNot disclosed
Tirzepatide$299/mo$179/mo
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
yourEra

Graded #23 · B

Strengths

  • Transparent, publicly listed pricing — many compounded competitors hide price behind a quiz
  • Both semaglutide and tirzepatide, not a single-drug menu, plus NAD+ and microdosing lines
  • Markets a 50-state licensed-clinician network; no insurance required, HSA/FSA accepted
  • Optional yourEra Optimum membership adds 1:1 coaching, a nutritionist, at-home lab draws and wearables

Where it loses points

  • Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Wegovy/Ozempic/Zepbound)
  • Mid-market pricing ($199 sema / $299 tirz) — above the cheapest compounders
  • No brand-name lane and no oral route — weekly injectable only
  • Thin independent footprint; the 50-state and efficacy claims are self-reported
Gala Health

Graded #8 · B

Strengths

  • Low compounded entry — tirzepatide $179/mo, microdose from $149, 3-month plans from $199
  • Available in all 50 states
  • Keeps a brand-name path open (Ozempic listed at $1,299)
  • HRT and menopause care available alongside GLP-1

Where it loses points

  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is priced steeply at $1,299
  • No oral or sublingual route offered yet
  • Newer operator (Gala GLP-1 by AI Coaching Inc) with a shorter public record

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 34 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard